Patent information
IP India · live recordApplication number
202517095213
Filing date
03 October 2025
Status
Application Awaiting Examination
Publication number
52/2025
Publication type
INA
Invention field
Chemical
Abstract
The disclosure relates to a combination of (i) an antibody-drug conjugate (ADC) comprising an anti-CEACAM5 antibody, (ii) a VEGFR-2 inhibitor, and (iii) an anti-PD-1 antibody or anti-PD-L1 antibody, for use in the treatment of a cancer.
Applicants
2France
SANOFI
46 avenue de la Grande Armée
75017 PARIS
U.S.A.
ELI LILLY AND COMPANY
Lilly Corporate Center
INDIANAPOLIS, Indiana 46285
Inventors
2France
CHADJAA, Mustaphac/o SANOFI, Patent Department
46 avenue de la Grande Armée
75017 PARIS
U.S.A.
DENNIS, Philipc/o SANOFI, Patent Department
450 Water Street
CAMBRIDGE, Massachusetts 02141
Documents
Sign in to openApplication documents
1
202517095213-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [03-10-2025(online)].pdf
03 Oct 2025
2
202517095213-STATEMENT OF UNDERTAKING (FORM 3) [03-10-2025(online)].pdf
03 Oct 2025
4
202517095213-Sequence Listing in PDF [03-10-2025(online)].pdf
03 Oct 2025
5
202517095213-REQUEST FOR EXAMINATION (FORM-18) [03-10-2025(online)].pdf
03 Oct 2025
6
202517095213-FORM 18 [03-10-2025(online)].pdf
03 Oct 2025
7
202517095213-FORM 1 [03-10-2025(online)].pdf
03 Oct 2025
8
202517095213-DRAWINGS [03-10-2025(online)].pdf
03 Oct 2025
9
202517095213-DECLARATION OF INVENTORSHIP (FORM 5) [03-10-2025(online)].pdf
03 Oct 2025
10
202517095213-COMPLETE SPECIFICATION [03-10-2025(online)].pdf
03 Oct 2025
11
202517095213-FORM-26 [09-12-2025(online)].pdf
09 Dec 2025